FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine. The use of eslicarbazepine or eslicarbazepine acetate for treating epilepsy in the patients previously treated with a drug which was a substrate for P- glycoprotein (P-gp) or multiple drug resistance (MRP) proteins, wherein epilepsy is refractory epilepsy and a refractory condition of epilepsy is an effect of P-gp and/or MRP overexpression. The pharmaceutical composition contains eslicarbazepine or eslicarbazepine acetate, and a pharmaceutically acceptable carrier for treating epilepsy in the patient previously treated with a drug which was a substrate for P- glycoprotein or multiple drug resistance (MRP) proteins.
EFFECT: invention provides higher clinical effectiveness.
12 cl, 2 tbl, 1 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT USING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE | 2012 |
|
RU2639120C2 |
| APPLICATION OF DERIVATIVES OF 5H-DIBENZ/b, f/AZEPIN-5-CARBOXAMIDE IN TREATMENT OF NEUROPATHIC PAIN AND NEUROLOGIC DISORDERS | 2007 |
|
RU2457845C2 |
| ESLICARBAZEPINE ACETATE AND METHODS FOR APPLYING THEREOF | 2005 |
|
RU2417085C2 |
| NOVEL 3,5-DIVINYL-PYRAZOLE DERIVATIVES FOR MEDICAL USE | 2015 |
|
RU2695062C2 |
| METHOD OF USAGE OF (HALO BENZYLOXY)BENZYLAMINO-PROPANAMIDE FOR PRODUCTION OF MEDICATIONS WITH SELECTIVE MODULATING ACTIVITY ON SODIUM AND/OR CALCIUM CHANNELS | 2005 |
|
RU2391973C2 |
| METHOD, MEDICINAL FORMULATION AND SETS FOR ENHANCING ORAL BIOLOGICAL AVAILABILITY OF PHARMACEUTICAL AGENTS | 2003 |
|
RU2296561C2 |
| METHOD OF TREATING DISEASES, ASSOCIATED WITH REDUCED BDNF PRODUCTION | 2013 |
|
RU2555344C2 |
| DERIVATIVE OF PYRROLIDINE ACETAMIDE OR ITS COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | 2000 |
|
RU2261093C2 |
| CRYSTALLINE FORM OF 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | 2009 |
|
RU2503662C2 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
